Stanley Capital buys French Pharma group Laboratoire XO

• Lab XO has a turnover of €60 million
• The group has 26 brands a distribution network of more than 45 countries
• The acquisition will serve as a platform investment with further add-on investments planned

Stanley Capital Partners (SCP) announced on Tuesday that it has bought a majority stake in French pharmaceutical group Laboratoire XO from Ares Management. The group, headquartered in Saint Cloud, was founded in 2015 and has a turnover of €60 million. The group has 26 brands and a distribution network of more than 45 countries.

SCP, based in London, will support Lab XO’s next phase of growth and the acquisition will serve as a platform investment with further add-on investments planned. Lab XO has grown both organically and through 18 add-on acquisitions. The group specialises in mature market authorisations to sell and market drugs across various therapeutic areas such as pain, central nervous, cardiology, oral care, and women’s health. The deal brings SCP’s assets under management to $440 million.

“SCP is pleased to partner with Karine Pinon and her impressive management team to accelerate Lab XO’s growth with a global footprint,” said Simon Cottle, SCP founding partner.

Stanley Capital Partners is a London-based European-focused mid-market private equity firm. It looks to invest in companies in the healthcare, technology and resource efficiency sectors. SCP targets businesses with enterprise values of $250 million to $2.5 billion.